Abstract 169P
Background
Pleural mesothelioma (PM) and non-small cell lung cancer (NSCLC) are aggressive thoracic malignancies with different cells of origin, pathogenesis and genetic features. Despite both tumors are treated with chemotherapy and immunotherapy, patients with PM and NSCLC exhibit varying responses. The aim of this study is to characterize the differences in tumor infiltrating immune cell populations in PM and NSCLC using high-dimensional flow cytometry analysis.
Methods
Fresh-frozen tumors derived from 42 PM and 30 NSCLC patients with available clinical data were analyzed. Single-cell suspensions were stained with a panel of 33 markers and samples were acquired using a Spectral Analyzer. An R-based pipeline for the in-depth characterization of the immune cells subsets was developed. Machine learning methods were used for unsupervised phenotypes discovery and differential abundant analysis was carried out to identify differences between samples. Correlation analysis with available clinical data was performed.
Results
By using high-dimensional single-cell analysis, 18 tissue-resident and invading immune cells subsets within the tumor immune microenvironment (TIME) of PM and NSCLC samples were identified. The comparison between the two tumor entities reveled significant differences in the tumor landscape, with increased infiltration of CD4+ and CD8+ T cell subsets in NSCLC compared to PM. While NSCLC tumors share similar tumor infiltrating immune cell subsets, PM tumors cluster in three distinct subgroups. Specifically, the subgroup with decreased infiltration of B cells and increased presence of tumor-associated macrophages is characterized by a significant worse overall survival (6 vs 18 vs 27 months, p=0.00012).
Conclusions
Our findings demonstrate significant differences in the composition of the TIME between PM and NSCLC, especially in T cell abundance. These disparities offer insights into the varying responses to immunotherapy. Moreover, we highlight the pivotal role of the TIME in predicting PM patient outcomes. These findings may be crucial to optimize immunotherapy for these malignancies, potentially leading to improve patients' outcomes.
Legal entity responsible for the study
The authors.
Funding
Stiftung für Angewandte Krebsforschung (SAKF).
Disclosure
I. Opitz: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, BMS; Financial Interests, Personal, Other, Proctorship: Intuitive; Financial Interests, Institutional, Research Grant: Medtronic, Roche. A. Curioni-Fontecedro: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Meyer Squibb, Boehringer Ingelheim, MSD, Novartis, Amgen, Roche, Takeda, Janssen; Non-Financial Interests, Personal, Leadership Role: Swiss Academy for Clinical Cancer Research (SAKK); Non-Financial Interests, Personal, Principal Investigator, of clinical trials: Roche; Non-Financial Interests, Personal, Principal Investigator, Clinical Trials: Takeda, MSD, Bristol Meyer Squibb, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors
Presenter: Jan Podhorec
Session: Poster Display
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display